BioCentury

7:00 AM GMT, Mar 26, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Finance

Highlights of weekly biotech stock moves

Regulatory milestones

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) lost $1.10 to $14 last week after announcing EMA accepted for review an MAA for lomitapide to treat homozygous familial hypercholesterolemia (HoFH).

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) gained $0.31 to $15.72 last week even though FDA's Oncologic Drugs Advisory Committee voted 13-1 that Taltorvic ridaforolimus from partner Merck & Co. Inc. (NYSE:MRK) did not demonstrate a favorable benefit-risk profile as a maintenance therapy for metastatic soft tissue or bone sarcoma patients with stable disease following chemotherapy. The PDUFA date is June 5 (see "Defining Meaningful," A12).

Gilead Sciences Inc. (NASDAQ:GILD) gained $0.22 to $46.85 on Friday after FDA's Antiviral Drugs Advisory announced it will meet

Read the full 1070 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.